---

Medicina de precisión en cáncer de ovario con Olaparib: importancia de la determinación de BRCA germinal y somático

1

Introduction

2

Número de diapositiva 3

3

Defining BRCAness Phenotype

4

Defining BRCAness Phenotype

5

Número de diapositiva 6

6

Número de diapositiva 7

7

Número de diapositiva 8

8

Study 19: To assess the efficacy and safety of Olaparib as maintenance treatment in HGSOC: A randomised, double-blind, placebo-controlled Phase II maintenance study 265 patients in 82 investigational sites in 16 countries

9

Olaparib met the primary endpoint of improving PFS in the OVERALL study population

10

More than 50% patients had a known deleterious BRCAm (Pre-planned BRCA testing)

11

Olaparib significantly prolonged PFS in platinum-sensitive relapsed HGSOC

12

BRCAness Phenotype

13

Número de diapositiva 14

14

BRCA-Like signature

15

HRD Assays: Lines of Research

16

WHO to test for gbrca mutations?

17

Número de diapositiva 18

18

WHO to test?

19

What about SOMATIC Testing?

20

Which one FIRST?

21

WHEN to test?

22

CONCLUSIONS

23

Gracias

24

Número de diapositiva 25

25

Our actual clinical practice. Our challenges

26

HRD Assays: ARIEL 2

27

Ariel 2: Refinement of prespecified cutoff for genomic LOH

28

Phase III ENGOT-Ov16/NOVA Trial: To assess the efficacy and safety of Niraparib as maintenance treatment in HGSOC

29

NOVA Trial: PFS by gBRCA status

30

HRD Assays: HRD Score

31

HRD Assays: HRD Score

32

HRD Assays: HRD Score

33